Effepharm said it has published the results of Uthever® Nicotinamide Mononucleotide (NMN) research on Frontier in Aging, an authoritative international journal on aging mechanisms.Uthever® NMN, an endogenous compound, has proved safe and improved the NAD+/NADH in the human body, thus realizing the a
A health expert recommended using pneumococcal vaccines, including Pfizer’s, for Covid-19 patients, noting that respiratory infection causes most of the hospitalization of those who developed sequelae even after a full recovery.The World Health Organization defines long Covid as cases that begin wit
Shinpoong Pharmaceutical, already working on multinational phase 3 trials of antimalarial treatment Pyramax in Covid-19 patients, said it would begin a new phase 2 study in Korea.The company said that the new study aims to confirm Pyramax’s effect against the Omicron variant.On Monday, the Ministry
HK inno.N said Tuesday that it has discovered next-generation immune-cancer antibodies in collaboration with Y Biologics. It added that the two companies would use this discovery to expand their research portfolio in antibody treatments and cell therapies such as CAR-T and CAR-NK.Antibodies are prot
Samsung Biologics said it would participate in the world’s largest biopharmaceutical exhibition, "2022 BIO International Convention,” from June 13-16 in San Diego, Calif., organized by the Biotechnology Innovation Organization.BIO holds the annual event in major U.S. cities with bio-clusters, provid
Dongkook Pharmaceutical said Monday it has signed a business agreement with Efil Bioscience to promote their joint research into new drugs.The two companies aim to develop promising new drugs, derive one or more non-clinical candidate substances by the end of this year, and conduct non-clinical rese
Pfizer Korea halted the supply of Vyndaqel Cap. 20 mg (Ingredient: Tafamidis), a transthyretin amyloid polyneuropathy (ATTR-PN) treatment, due to quality issues.The drug, which delays peripheral nerve damage in adult patients with stage 1 symptomatic polyneuropathy, has no substitute drug with the s
Ipsen Korea said it aims to provide a better treatment option for Korean renal cell cancer patients with a Cabometyx and Opdivo combination therapy after receiving approval to use the treatment as first-line therapy."Kidney cancer is a type of cancer difficult to detect at an early stage, and chemot
Dong-A ST said Friday that it has released non-clinical research results on the new drug candidate, DA-1726, in a poster session at the annual American Diabetes Association (ADA) conference.DA-1726 is a new drug under development as an oxyntomodulin analog-based obesity and diabetes treatment, which
Samsung Bioepis presented the phase 3 clinical trial results of its Soliris biosimilar, eculizumab (SB12), at the European Hematology Association 2022 (EHA2022) congress in Vienna on Friday.Soliris is a humanized monoclonal antibody produced in the NS0 cell line by recombinant DNA technology. It is
Sanofi-Aventis Korea’s labor union embarked on industrial action on Tuesday, as the wage negotiation with the management failed to narrow differences.According to the union, it has requested the management to reflect on the company’s improved sales performance last year on deciding this year’s wage
The European Medicines Agency (EMA) included Celltrion’s antibody treatment Regkirona (regdanvimab) in the list of critical medicines for Covid-19.EMA’s Medicines Shortages Steering Group (MSSG) adopted the list of critical drugs for the Covid-19 public health emergency on Tuesday, according to the
Eutilex said it would begin clinical trials for a CAR-T treatment to treat solid cancer for the first time in Korea.The company plans to submit an investigational new drug application (IND) for its CAR-T treatment pipeline in the second half of this year and has already secured non-clinical efficacy
Novartis said that the Ministry of Food and Drug Safety has approved Scemblix (Ingredient: asciminib), a treatment for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).Semblix treats adult patients with Ph+ CML in the chronic stages who have received treatment
Hanmi Pharmaceutical said Wednesday that the number of its drugs under development that have won orphan drug designations (ODD) has increased to 20, breaking its own record in the Korean biopharmaceutical industry.Most recently, Hanmi received an ODD from the European Medicines Agency (EMA) for LAPS
List Biotherapeutics, a U.S. subsidiary of Genome & Company, said that it has started the construction of its microbiome treatment production facility in Fishers City, Ind.Established in October 2020, List Biotherapeutics plans to build a large-scale microbiome production facility in Fishers Life Sc
Celltrion Pharmaceutical said it would exclusively market two diabetes treatment lineups – Nesina and Actos – it took over from Takeda Pharmaceutical. Jeil Pharmaceutical has marketed the two treatments.Celltrion has decided to end the joint sales contract at the end of this month and start direct s
Korea AI Center for Drug Discovery and Development (KAICD) said Wednesday that it would recruit expert instructors to develop and teach artificial intelligence (AI) to facilitate drug discovery and practical cooperative research.As an affiliated organization of the Korea Pharmaceutical and Bio-Pharm
The number of patients registered for phase 3 clinical trials of GNT Pharma’s stroke treatment, Nelonemdaz, has exceeded 100, raising expectations for completing all related trials in 2023 as scheduled, the company said Tuesday.Nelonemdaz is the first drug candidate worldwide that received approval
Amgen Korea and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha (evolucumab), lipid-lowering drugs for atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia starting in June.Under the agreement, Amgen Korea and Jeil Pharmaceutical will conduct Repatha sale